

(*R*)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridines: Novel Optically Active Compounds with Strong 5-HT_{1A} Receptor Binding Ability Exhibiting Anticonflict Activity and Lessening of Memory Impairment[†]

Hiromu Kawakubo,*[‡] Seiji Takagi,[‡] Yuuji Yamaura,[‡] Shinichi Katoh,[‡] Yumiko Ishimoto,[‡] Tadashi Nagatani,[§] Daisuke Mochizuki,[§] Tomoko Kamata,[‡] and Yasuharu Sasaki[§]

Synthetic and Physical Sections, Institute of Life Science, Asahi Chemical Industry Company, Ltd., Asahi-Machi 6-2700, Nobeoka, Miyazaki 882, Japan, and Computer Science Department, Asahi Chemical Industry Company, Ltd., 2-1 Samejima, Fuji, Shizuoka 416, Japan

Received June 7, 1993*

(*R*)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridine derivatives (60-114) were synthesized. The (*R*)-isomers have affinity for the 5-HT_{1A} receptor while the (*S*)-isomers have no such ability. The affinity of the (*R*)-isomers was discussed on the basis of structure-activity relationships between the affinity and hydrophobicity of the (*R*)-isomers. Compounds 71 and 107, which are representative derivative compounds, have anticonflict activity and lessening of memory impairment. In particular, compound 107 cannot bind to receptors other than the 5-HT_{1A} receptor, demonstrating that it is a unique compound with a different mechanism of action from that of conventional anxiolytics.

Introduction

The neurotransmitter 5-HT has recently received much attention. 5-HT is involved in numerous physiological (e.g. hemodynamics, feeding, sleeping) and pathophysiological (e.g. depression, hypertension, migraine anxiety) processes and interacts with various distinct membrane receptors. Buspirone¹ is widely used as an anxiolytic which binds to the 5-HT_{1A} receptor. Tandospirone² is now under clinical trial. However, since these drugs also bind to the DA₂ receptor,³ it is difficult to explain the mechanisms of their anticonflict effect only by their affinity for the 5-HT_{1A} receptor. We reported on racemic 1,2,3,4-tetrahydro[1]benzothieno[2,3-*c*]pyridine derivatives⁴ with selective affinity for the 5-HT_{1A} receptor.

In this paper, we report that only (*R*)-isomers of 1,2,3,4-tetrahydro[1]benzothieno[2,3-*c*]pyridines can bind selectively to the 5-HT_{1A} receptor, while their (*S*)-isomers⁵ cannot. We describe the synthesis of optically active 1,2,3,4-tetrahydro[1]benzothieno[2,3-*c*]pyridines as well as their anticonflict activities, lessening of memory impairments, and structure-activity relationships.

Chemistry

We synthesized novel 2- or 3-substituted (*R*)-1,2,3,4-tetrahydro[1]benzothieno[2,3-*c*]pyridines (60-114) as shown in Scheme I. The optical resolution was the most important step in our synthetic routes. (*R*)-Thiotryptophan 2 (99.7% *ee*) was obtained by deacetylation⁶ of 17 with Acylase.⁸ The ester 3 was synthesized from 2 using the standard procedure.^{9,10} (*R*)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridine-3-carboxylic acid methyl ester 4 was obtained from 3 according to the standard procedure of Pictet-Spengler isoquinoline synthesis.¹¹⁻¹³ The reaction¹⁴ of 4 with (Boc)₂O/NEt₃ gave 5, which was hydrolyzed with NaOH to give (*R*)-*N*-Boc acid 6 (91%) and (*S*)-*N*-Boc acid 7 (9%). Treatment¹⁵ of a mixture 6

and 7 with D-(+)-1-phenylethylamine in *i*-PrOH yielded recovered 7 and D-(+)-1-phenylethylamine salt of 6 which was acidified with HCl to give 6. The acid 6 was converted to 8-59 by reaction with various amines and alcohols in the presence of DPPA/NEt₃. The compounds 60-111 were obtained by treatment of 8-59 with 1 N HCl in AcOEt. The acid 112 was obtained by treatment of 6 with 1 N HCl in AcOEt. The compounds (113-114) were synthesized by the reaction of 63 with MeI, *p*-methylbenzoyl chloride, and NEt₃ in CHCl₃.

Pharmacological Methods

Affinity for the 5-HT_{1A} receptor¹⁶ was measured by use of [³H]-8-OH-DPAT and receptor preparation obtained from hippocampus of male Sprague-Dawley rats. The procedure is described in the Experimental Section.

Anticonflict activity was evaluated by a water lick conflict test¹⁷ using groups of male Wistar rats. The procedure is described in the Experimental Section.

Lessening of memory impairment was evaluated by a passive avoidance test^{18,19} using groups of male ddY mice. The procedure is described in the Experimental Section.

Result and Discussion

1. Affinity of Optically Active 1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridines for the 5-HT_{1A} Receptor. The affinity of the (*R*)-compounds for the 5-HT_{1A} receptor is shown as the inhibition percentage in Tables I and II. The large difference in affinity for the 5-HT_{1A} receptor between (*R*)- and (*S*)-isomers is shown in typical cases with 63 and 107 (Table I); the IC₅₀ value of (*S*)-isomer of 63 or 107 is more than 184- and 94-times that of 63 or 107. IC₅₀ (nM) values for other compounds which showed more than 65% inhibition are also listed in Table I. These compounds have strong affinity of the order of 10-100 (nM).

2. Relationship between Hydrophobicity of the Compound and Affinity for the 5-HT_{1A} Receptor. The retention time (*t*_r) of the compound on reversed-phase HPLC (Table I) was employed as a measure of the hydrophobicity.²⁰ The affinity for the 5-HT_{1A} receptor (Table I) was plotted against the hydrophobicity (log *t*_r) as shown in Figure 1. A good correlation was observed up


[†] Abbreviations: 5-HT, serotonin; DA, dopamine; BZP, benzodiazepine; HPLC, high-performance liquid chromatography; (Boc)₂O, di-*tert*-butyl dicarbonate; DPPA, diphenyl phosphorazidate.

[‡] Synthetic Section, Institute of Life Science.

[§] Pharmaceutical Section, Institute of Life Science.

[‡] Computer Science Department.

* Abstract published in *Advance ACS Abstracts*, October 1, 1993.

Scheme 1^a

^a (A) Acylase; (B) SOCl₂/MeOH; (C) 30% HCHO/EtOH-H₂O; (D) (Boc)₂O/NEt₃; (E) NaOH/H⁺; (F) D-(+)-PhCH(CH₃)NH₂; (G) RH/DPPA/NEt₃/DMF; (H) 1 N HCl/AcOEt; (I) CH₃I or *p*-methylbenzoyl chloride/NEt₃ (R = HNC₆H₁₁).

to the hydrophobicity of 1.3. But the hydrophobicity is more than 1.3 in the case of compounds 105 and 106, with resulting decreased affinity for the 5-HT_{1A} receptor. Compounds 75 and 87-93 without an NH group showed no affinity, probably because of their tertiary amide structure (Table I).

The result indicates that large molecules can bind to the receptor and that the affinity for the 5-HT_{1A} receptor increases as the molecular size increases. Thus it is concluded that the presence of (R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine skeleton and the attachment of an appropriate hydrophobic group are necessary for the good affinity for the 5-HT_{1A} receptor.

3. Anticonflict Activity and Lessening of Memory Impairment with Representative Compounds 71 and 107. The most active compounds 71 and 107 were examined following oral administration for anticonflict activity in the water lick conflict test where they were as potent as diazepam (Table III). In addition, the compounds 71 and 107 was also tested with respect to the ability to reverse scopolamine-induced amnesia in a passive avoidance test used to assess memory impairment. While the compounds were active and increased latency over that seen with diazepam or scopolamine, they did not return latency to that seen in control animals.

4. Binding Ability of Compound 107 to Various Receptors. Binding ability of compound 107 to various receptors other than 5-HT_{1A} were in order BZP (>1.0 × 10⁻⁴ M), GABA_B (>1.0 × 10⁻⁴ M), DA₁ (3.0 × 10⁻⁵ M), DA₂ (>1.0 × 10⁻⁴ M), α₁ (6.0 × 10⁻⁶ M), α₂ (1.0 × 10⁻⁴ M), β₁ (>1.0 × 10⁻⁴ M), β₂ (>1.0 × 10⁻⁴ M), 5-HT₂ (>1.0 × 10⁻⁴ M), 5-HT₃ (>1.0 × 10⁻⁴ M). Compound 107 bound selectively to the 5-HT_{1A} ((5.31 ± 0.07) × 10⁻⁸ M) receptor in Table IV. On the other hand, both tandospirone (DA₂ = 2.8 × 10⁻⁶ M³, 5-HT_{1A} = 2.7 × 10⁻⁸ M), and buspirone (DA₂ = 9.0 × 10⁻⁸ M³, 5-HT_{1A} = 1.5 × 10⁻⁸ M) also bound to the DA₂ receptor in Table IV, so that mechanism of action cannot be explained just from the 5-HT_{1A} receptor binding. Indeed drug discrimination assay systems are widely used for characterization of drugs. However, this procedure is usually employed to compare the so called "discriminative stimulus effect" of the drug. It is well-known that this discriminative stimulus does not always reflect the efficacy of the drug. In addition, in our

preliminary data compound 107 seems not to be a simple agonist for the 5-HT_{1A} receptor different from 8-OH-DPAT. Discriminative studies are in progress to characterize compound 107 as a 5-HT_{1A} ligand; however, we suspect that a drug discrimination assay is not adequate for discussing whether compound 107 is an agonist or an antagonist for the 5-HT_{1A} receptor. From current pharmacological studies, compound 107 clearly inhibited forskolin-stimulated adenylate cyclase activity in rat hippocampal membrane through the 5-HT_{1A} receptor similar to the inhibitory effect of typical 5-HT_{1A} agonist (e.g. 8-OH-DPAT, tandospirone, buspirone). The potency seems to be weaker compared with 8-OH-DPAT. Moreover the anticonflict effect of compound 107 was clearly antagonized by NAN-190, 5-HT_{1A} antagonist. Therefore presently we suspect compound 107 is an agonist or a partial agonist for the postsynaptic 5-HT_{1A} receptor. Therefore, it was concluded that compound 107 is a unique compound which selectively binds to the 5-HT_{1A} receptor and exhibits anticonflict activity and lessening of memory impairment.

Conclusion
























(R)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-c]pyridine derivatives (60-114) were synthesized. The (R)-isomers have affinity for the 5-HT_{1A} receptor while the (S)-isomers have no such ability. The large (R)-isomer can bind to the receptor, and the affinity for the 5-HT_{1A} receptor increases as the molecular size increases. The presence of the (R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine skeleton and the attachment of an appropriate hydrophobic group are necessary for the good affinity for the 5-HT_{1A} receptor.

The most active compounds, 71 and 107, showed anticonflict activity in the water lick conflict test where they were as potent as diazepam. While the compounds increased latency over that seen with diazepam or scopolamine, the ability to reverse scopolamine-induced amnesia in a passive avoidance test was used to assess memory impairment. In particular, the representative compound 107 demonstrated anticonflict activity and lessening of memory impairment with strongly selective 5-HT_{1A} receptor binding.

Table I. Physical Data and 5-HT_{1A} Binding Data of 3-Substituted (*R*)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridines

compd	R	yield, ^a %	mp, ^b °C	formula ^c	retention time, ^d min	% inhibition of 5-HT _{1A} binding in compd (10 ⁻⁶ M) [IC ₅₀ ^e (nM) of 5-HT _{1A}]
60		72	243–244	C ₁₅ H ₁₆ N ₂ OS·HCl	2.79	10.6
61		74	267–268	C ₁₆ H ₁₈ N ₂ OS·HCl	3.56	71.3 [232.4]
62		79	284–285	C ₁₇ H ₂₀ N ₂ OS·HCl	4.77	83.0 [110.9]
63		75	264–266	C ₁₈ H ₂₂ N ₂ OS·HCl ^f	6.72	92.7 [27.2]
64		79	275–276	C ₁₉ H ₂₄ N ₂ OS·HCl	10.56	94.7 [28.4]
65		81	263–264	C ₂₀ H ₂₆ N ₂ OS·HCl	15.71	96.0 [22.9]
66		79	268–272	C ₁₉ H ₂₄ N ₂ OS·HCl	11.45	94.6 [32.4]
67		82	265–267	C ₁₉ H ₂₄ N ₂ OS·HCl	8.99	94.4 [28.0]
68		83	266–268	C ₂₂ H ₃₀ N ₂ OS·HCl	68.11	94.5 [52.7]
69		78	278–280	C ₁₉ H ₂₂ N ₂ OS·HCl	7.77	89.2 [66.4 ± 5.9]
70		75	277–280	C ₂₂ H ₂₆ N ₂ OS·HCl	23.65	91.2 [61.6]
71		62	265–266	C ₁₈ H ₂₂ N ₂ O ₂ S·HCl	3.44	80.6 [148.5 ± 11.0]
72		51	268–270	C ₁₈ H ₂₂ N ₂ O ₂ S·HCl	12.45	32.6
73		49	130–132	C ₁₈ H ₂₂ N ₂ O ₂ S·HCl	2.55	33.7
74		44	298–300	C ₁₈ H ₂₄ N ₃ OS·3HCl	2.31	12.4
75		81	252–253	C ₁₉ H ₂₄ N ₂ OS·HCl		2.9
76		79	243–245	C ₁₉ H ₂₄ N ₂ OS·HCl	12.36	95.5 [20.2]
77		75	282–285	C ₁₈ H ₂₃ N ₃ OS·2HCl ^k	5.53	6.3
78	HN(CH ₂) ₂ CH ₃	77	229–234	C ₁₅ H ₁₈ N ₂ OS·HCl	3.35	41.2
79	HN(CH ₂) ₃ CH ₃	77	248–249	C ₁₆ H ₂₀ N ₂ OS·HCl	4.61	63.0
80	HN(CH ₂) ₄ CH ₃	76	242–243	C ₁₇ H ₂₂ N ₂ OS·HCl	7.68	83.2
81	HN(CH ₂) ₅ CH ₃	72	238–240	C ₁₈ H ₂₄ N ₂ OS·HCl	14.40	89.2 [91.2]
82	HN(CH ₂) ₆ CH ₃	69	236–238	C ₁₉ H ₂₆ N ₂ OS·HCl	28.93	84.4 [126.2]
83	HNCH ₂ CH(CH ₃) ₂	59	271–273	C ₁₆ H ₂₀ N ₂ OS·HCl	4.36	64.6
84	HNC(CH ₃) ₃	49	254–259	C ₁₆ H ₂₀ N ₂ OS·HCl	4.41	43.1
85	HNCH ₂ C(CH ₃) ₃	70	256–257	C ₁₇ H ₂₂ N ₂ OS·HCl	6.24	81.4
86	HNCH(CH ₂ CH ₃) ₂	72	249–250	C ₁₇ H ₂₂ N ₂ OS·HCl	5.53	66.2 [126.5]
87	N(CH ₂ CH ₃) ₂	81	254–259	C ₁₆ H ₂₀ N ₂ OS·HCl		1.8
88		83	250–252	C ₁₇ H ₂₀ N ₂ OS·HCl		0.3


Table I (Continued)

compd	R	yield, ^a %	mp, ^b °C	formula ^c	retention time, ^d min	% inhibition of 5-HT _{1A} binding in compd (10 ⁻⁶ M) [IC ₅₀ ^e (nM) of 5-HT _{1A}]
89		72	244–245	C ₁₆ H ₁₈ N ₂ O ₂ S·HCl		0.0
90		31	266–267	C ₁₆ H ₁₉ N ₃ OS·2HCl		0.0
91		55	258–260	C ₁₇ H ₂₁ N ₃ OS·2HCl		0.1
92		59	252–254	C ₂₀ H ₂₁ N ₃ OS·2HCl		2.5
93		35	258–260	C ₁₇ H ₂₁ N ₃ OS·2HCl		0.0
94		49	247–248	C ₁₆ H ₁₉ N ₃ OS·2HCl ^l	2.31	42.1
95		51	261–263	C ₁₇ H ₂₁ N ₃ OS·2HCl	2.88	68.6 [210.9]
96		69	268–270	C ₁₇ H ₂₂ N ₄ OS·3HCl		2.9
97		62	261–263	C ₁₆ H ₁₉ N ₃ O ₂ S·2HCl ^m	2.57	21.2
98		60	260–261	C ₁₉ H ₂₆ N ₄ OS·3HCl	2.31	73.0
99		68	252–254	C ₁₉ H ₂₄ N ₄ O ₂ S·3HCl		1.9
100		80	268–270	C ₁₈ H ₁₆ N ₂ OS·HCl	5.59	68.3 [272.0]
101		79	261–265	C ₁₉ H ₁₈ N ₂ OS·HCl	6.03	77.3
102		73	262–266	C ₂₀ H ₂₀ N ₂ OS·HCl	8.11	92.5 [58.4]
103		72	245–250	C ₂₀ H ₂₀ N ₂ OS·HCl	7.31	79.1
104		71	261–265	C ₂₀ H ₂₀ N ₂ OS·HCl	4.36	84.4 [133.1]
105		77	268–274	C ₂₂ H ₂₄ N ₂ OS·HCl	29.23	54.4
106		78	285–287	C ₂₃ H ₂₆ N ₂ OS·HCl	46.29	24.3
107		81	240–245	C ₂₀ H ₁₈ N ₂ O ₃ S·HCl	5.75	90.0 [53.1 ± 0.7]
108		75	218–221	C ₁₇ H ₁₉ NO ₂ S·HCl	10.12	88.1 [120.6]
109		69	286–288	C ₁₈ H ₂₁ NO ₂ S·HCl	17.57	93.3 [50.4]
110		71	226–231	C ₁₉ H ₂₃ NO ₂ S·HCl	30.13	94.3 [55.2]
111		69	222–224	C ₂₀ H ₂₅ NO ₂ S·HCl	52.80	95.0 [67.3]
112	OH	88 ^a	>300	C ₁₂ H ₁₁ NO ₂ S		1.2
(S)-isomer of 63		71	263–267	C ₁₈ H ₂₂ N ₂ OS·HCl		[>5000]
(S)-isomer of 107		79	241–245	C ₂₀ H ₁₈ N ₂ O ₃ S·HCl		[>5000]


^a The yield comes from G and H synthetic steps in Scheme I. ^b Recrystallization solvent was EtOH/ether. ^c Analyses for C, H, N, S were within ±0.4% of the theoretical values unless otherwise noted. ^d Compound was not shown in inhibition (<5%) of 5-HT_{1A} binding in compd (10⁻⁶ M) in Table I. HPLC condition: solvent; CH₃CN/0.1 M NH₄Cl = 3:7, solvent speed; 1 mL/min; detected wavelength; 254 nm. ^e Most of the data come from single data determination; however, compounds 69, 71, and 107 were returned in triplicate and are given as their mean ± SEM. ^f S: calcd, 9.14; found, 9.69. ^g These amines were diastereomers. ^h S: calcd, 7.97; found, 8.43. ⁱ N: calcd, 11.23; found, 11.69. ^m S: calcd, 8.21; found, 7.79. ⁿ The yield comes from H synthetic step in Scheme I.

Table II. Physical Data and 5-HT_{1A} Binding Data of 2-Substituted (*R*)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridines

12,8 5-HT_{1A} names

compd	R ₂	yield, ^a %	mp, ^b °C	formula ^c	% inhibition of 5-HT _{1A} binding in compd (10 ⁻⁶ M)
113	CH ₃	3.8	260–261	C ₁₉ H ₂₄ N ₂ OS· HCl	12.8
114		71	179–181	C ₂₀ H ₁₆ NO ₂ S	0.0

^a The yield comes from I synthetic step in Scheme I. ^b Recrystallization solvent was EtOH/ether. ^c Analyses for C, H, N, S were within ±0.4% of the theoretical values unless otherwise noted.

**Figure 1.** Plot of log (retention time) vs 5-HT_{1A} binding percent.**Table III.** Anticonflict Activity on Water Lick Conflict Test in Rats and Effect of Passive Avoidance Test in Scopolamine-Induced Amnesia in Mice of Compounds 71, 107, and Diazepam

compd (mg/kg po)	no. shocks in 5 min (no. of rats) ^{a,b}	latency to step through, s (no. of mice) ^{a,c}
control	12.5 ± 2.2 (19)	
diazepam (10)	25.6 ± 2.4*** (43)	
71 (1)	21.6 ± 5.4 (12)	
71 (3)	34.9 ± 7.9** (12)	
71 (30)	26.1 ± 5.5* (7)	
107 (1)	22.1 ± 3.9* (20)	
107 (3)	22.9 ± 4.5* (20)	
107 (10)	28.3 ± 5.5** (14)	
control		279.4 ± 9.2 (18)
scopolamine (1)		16.0 ± 1.6 (18)
diazepam (5)		10.6 ± 6.6*** (15)
71 (3)		68.2 ± 20.0* (18)
71 (10)		41.6 ± 4.7** (18)
71 (30)		50.8 ± 9.2** (18)
107 (1)		94.6 ± 2.3** (18)
107 (3)		89.0 ± 4.5* (18)
107 (30)		104.7 ± 6.9** (18)

^a **p* < 0.05; ***p* < 0.01; ****p* < 0.005 (Student's *t* test). ^b Number of shocks received in 5 min at each dose of compound. ^c Time of latency in seconds at each dose of compound.

Experimental Section

All melting points were determined with a Büchi 510 melting point apparatus and are uncorrected. Elemental analyses performed by Yanagimoto MT-3 were obtained for all new compounds and were within ±0.4% of the theoretical values unless otherwise noted. IR spectra were determined with a Hitachi IR-260-10 spectrometer. NMR spectra were recorded on a NEC JMX GX-400 instrument with tetramethylsilane as an internal standard. MS spectra were measured with an NEC

Table IV. Affinity for the 5-HT_{1A} and DA₂ Receptors of Compound 107, Buspirone, and Tansospirone

	compound 107 (M)	buspirone (M)	tansospirone (M)
affinity for the 5-HT _{1A} receptor	(5.31 ± 0.07) × 10 ⁻⁸	1.5 × 10 ⁻⁸ ^a	2.7 × 10 ⁻⁸ ^a
affinity for the DA ₂ receptor	> 1.0 × 10 ⁻⁴	9.0 × 10 ⁻⁸ ^b	2.8 × 10 ⁻⁸ ^b

^a Witkin, J. M.; Mansbach, R. S.; Barrett, J. E.; Bolger, G. T.; Skolnick, P.; Weissman, B. Behavioral Studies with Anxiolytic Drugs. IV. Serotonergic Involvement in the Effects of Buspirone on Punished Behavior of Pigeons. *J. Pharmacol. Exp. Ther.* 243, 970–977. ^b Grattini, S.; Caccia, C.; Mennini, T. Notes on Buspirone's Mechanism of Action. *J. Clin. Psych.* 1943, 12, 19–24. Hamik, A.; Okseberg, D.; Fischette, C.; Peroutka, S. J. Analysis of Tansospirone (SM-3977) Interactions with Neurotransmitter Receptor Binding Sites. *Biol. Psych.* 1990, 28, 99–109.

01-SG mass spectrometer. Column chromatography was carried out with silica gel 60 (0.063–0.200 mm, Wako Pure Chemical Industry, Ltd.). HPLC was carried out with Kaseisorb LC ODS-120-5 (4.5-mm i.d. × 150 mm, Tokyo Chemical Industry Company, Ltd.).

Synthetic Methods. Scheme I. (*R*)-2-Amino-3-[1]benzothiophene-3-ylpropionic Acid (2). Compound 1 (150 g, 570 mmol) was added to H₂O (500 mL), and the pH was adjusted to 6.5 with NaOH. Acylase 3000 units (1.0 g) and CoCl₂·6H₂O (72 mg, 72 μmol) were added to the reaction mixture, and the resulting mixture was stirred for 1 day at room temperature. Precipitates formed were collected by filtration to provide (*S*)-2-amino-3-[1]benzothiophene-3-ylpropionic acid (59.6 g, 269 mmol), [α]_D²⁵ = −9.17° (g/100 mL, 0.1 N HCl). The pH of the reaction solution was adjusted to 6.5 with 6 N HCl. Precipitates formed were collected by filtration to provide (*R*)-α-acetamido-β-[1]benzothiophene-3-ylpropionic acid (73.5 g, 279 mmol). The optical purity was 99.7% ee as determined by HPLC (hexane/2-PrOH/CF₃COOH, 90:10:0.1, Daicel Chemical Industries, Ltd., Chiralcel OJ). (*R*)-α-Acetamido-β-[1]benzothiophene-3-ylpropionic acid (500 g, 1.9 mol) was added to 5 N CH₃SO₃H (5 L), and the mixture was stirred for 7 h at 100 °C. After cooling, H₂O was added, and the pH was adjusted to 6.5 with 6 N NaOH. Precipitates formed were collected by filtration to provide (*R*)-2-amino-3-[1]benzothiophene-3-ylpropionic acid (400 g, 1.52 mol), [α]_D²⁵ = 9.80° (g/100 mL, 0.1 N HCl). IR (KBr): 3050, 1670, 1585 cm⁻¹.

(*R*)-α-Amino-3-[1]benzothiophene-3-ylpropionic Acid Methyl Ester Hydrochloride (3). Thionyl chloride (260 mL, 1.32 mol) was gradually added to dried MeOH (1.5 L) at −10 °C. The mixture was stirred for 30 min at −10 °C. Compound 2 (221.3 g, 1.00 mol) was added to the mixture, and the resulting mixture was stirred for 2 days at room temperature. After MeOH was removed under reduced pressure, Et₂O (500 mL) was added to the residue. Compound 3 (323.9 g, 856 mmol) was obtained by filtration in a yield of 90%. Mp: 156–157 °C. IR (KBr): 1740 cm⁻¹. Anal. (C₁₂H₁₄NO₂SCl): C, H, N, S.

(*R*)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-*c*]pyridine-3-carboxylic Acid Methyl Ester (4). Compound 3 (110.6 g, 407 mmol) and 30% HCHO (51 mL, 510 mmol) were dissolved in MeOH (1 L) and H₂O (1 L), and the mixture was stirred at 80 °C for 5 h. The reaction mixture was concentrated to about half its original volume. The pH was adjusted to 10 with NaHCO₃. The mixture was extracted with CHCl₃ (100 mL × 3). The CHCl₃ layer was washed with saturated aqueous brine (50 mL × 2) and dried on Na₂SO₄. CHCl₃ was removed under reduced pressure. The residue was recrystallized from CHCl₃ (100 mL) and Et₂O (100 mL) to provide compound 4 (74.1 g, 296 mmol) in a yield of 72%. Mp: 128–130 °C. IR (KBr): 2970, 2900, 1740, 1440, 1160, 760, 740 cm⁻¹. NMR (δ, CDCl₃): 2.25 (s, 2H), 3.10 (d, *J* = 2.5 Hz, 2H), 3.72–4.00 (m, 1H), 4.23 (s, 3H), 7.01–8.02 (m, 4H). Anal. (C₁₃H₁₃NO₂S): C, H, N, S.

2-(*tert*-Butoxycarbonyl)-(*R*)-1,2,3,4-tetrahydro[1]benzothieno[2,3-*c*]pyridine-3-carboxylic Acid Methyl Ester (5). Compound 4 (23.9 g, 96.6 mmol) and (Boc)₂O (23.9 g, 96.6 mmol) were dissolved in dry THF (30 mL), MeOH (80 mL), and NEt₃ (16.2 mL, 116 mmol), and the mixture was stirred at 60 °C for 2 h. The THF and MeOH solution was concentrated under

reduced pressure. The residue was dissolved in AcOEt (300 mL), and the solution was washed with an aqueous 10% citric acid solution (50 mL \times 2), an aqueous 5% NaHCO₃ solution (50 mL \times 2), and saturated aqueous brine (50 mL \times 2) and dried on Na₂SO₄. AcOEt was removed under reduced pressure, and compound 5 (32.6 g, 93.7 mmol) was recrystallized from CHCl₃ (60 mL) and petroleum ether (30 mL) in a yield of 79%. Mp: 179–181 °C. IR (KBr): 1740, 1700 cm⁻¹. Anal. (C₁₈H₂₁NO₄S): C, H, N, S.

2-(tert-Butoxycarbonyl)-(R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3-carboxylic acid (6). Compound 5 (5.77 g, 17.4 mmol) and 5 N NaOH (3.5 mL, 17.6 mmol) were dissolved in MeOH (50 mL), stirred at 100 °C for 1 h, and concentrated under reduced pressure. Aqueous 5% citric acid (300 mL) and CHCl₃ (300 mL) were added to the residue, and the mixture was shaken. The CHCl₃ extract was dried on Na₂SO₄ and concentrated to give 6 (91%) and 7 (9%) (5.03 g, 15.8 mmol). The mixture was dissolved in *i*-PrOH (50 mL) and added to D-(+)-1-phenylethylamine (1.91 g, 15.8 mmol), and then the mixture was stirred at 25 °C for 1 h and recrystallized in MeOH (25 mL), giving 2-(tert-butoxycarbonyl)-(R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3-carboxylic acid D-(+)-1-phenylethylamine salt (5.97 g, 13.6 mmol). This compound (5.97 g, 13.6 mmol) and 1 N HCl (31 mL) were dissolved in CH₂Cl₂ (30 mL) and stirred at 20 °C for 1 h, and the solution was washed with an aqueous 10% citric acid solution (50 mL \times 2) and saturated aqueous brine (50 mL \times 2), dried on Na₂SO₄, and then removed under reduced pressure. Compound 6 (4.41 g, 13.3 mmol) was recrystallized from AcOEt (10 mL) and *n*-hexane (30 mL) in a yield of 76%. Mp: 212–214 °C. IR (KBr): 1700, 1695 cm⁻¹. Anal. (C₁₇H₁₉NO₄S): C, H, N, S.

2-(tert-Butoxycarbonyl)-(R)-N-cyclopropyl-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3-carboxamide (8). Compound 6 (3.3 g, 10 mmol) and cyclopropylamine (0.63 g, 11 mmol) were dissolved in DMF (20 mL). A solution of DPPA (3.3 g, 12 mmol) in DMF (10 mL) and a solution of NEt₃ (1.53 mL, 11 mmol) in DMF (5 mL) were added to the solution under cooling and stirred at 0 °C for 1 h and further at 20 °C for 12 h. AcOEt (100 mL) was added to the reaction mixture. The mixture was washed with aqueous 5% citric acid (20 mL \times 2), aqueous Na₂CO₃ (20 mL \times 2), and saturated aqueous brine (20 mL \times 2). The AcOEt extract was dried on Na₂SO₄, concentrated, and purified through a silica gel column (CHCl₃) to give 8 (2.88 g, 7.7 mmol) in a yield of 77%. Mp: 182–184 °C. IR (KBr): 1700, 1670 cm⁻¹. Anal. (C₂₀H₂₄N₂O₃S): C, H, N, S.

(R)-N-Cyclopropyl-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3-carboxamide Hydrochloride (60). Compound 8 (2.88 g, 7.7 mmol) and 1 N HCl in AcOEt solution (10 mL) were dissolved in AcOEt (20 mL) at 80 °C for 1 h. The reaction mixture was allowed to stand overnight in a refrigerator, and the precipitated crystals were collected to give 60 (2.12 g, 6.86 mmol) in a yield of 89%. The optical purity was 99.8% ee as determined by HPLC (hexane/EtOH, 6:4, Daicel Chemical Industries, Ltd., Chiralpak AS). Mp: 243–244 °C. IR (KBr): 3250, 2940, 2700, 2600, 1690, 1680, 1540, 765, 740 cm⁻¹. NMR (δ , CDCl₃): 0.50–0.83 (m, 4 H), 2.81–3.24 (m, 1 H), 3.45–3.89 (m, 2 H), 4.16–4.50 (m, 1 H), 4.93–5.32 (m, 2 H), 5.72–5.98 (m, 1 H), 7.12–7.48 (m, 2 H), 7.65–7.82 (m, 2 H). Anal. (C₁₆H₁₈N₂O₃S·HCl): C, H, N, S.

(R)-1,2,3,4-Tetrahydro[1]benzothieno[2,3-c]pyridine-3-carboxylic Acid (112). Compound 6 (3.17 g, 10 mmol) and 1 N HCl in AcOEt solution (12 mL) were dissolved in AcOEt (20 mL) at 80 °C for 1 h. The reaction mixture was allowed to stand overnight in a refrigerator, and the precipitated crystals were collected to give 112 (2.05 g, 8.88 mmol) in a yield of 88%. The optical purity was 99.9% ee as determined by HPLC (25 mM CuSO₄, Daicel Chemical Industries, Ltd., Chiralcel WH.). Mp: >300 °C. IR (KBr): 3250, 2940, 2700, 2600, 1690, 1680, 1540, 765, 740 cm⁻¹. NMR (δ , DMSO-*d*₆): 2.38–4.44 (m, 5 H), 6.20–7.48 (m, 4 H). Anal. (C₁₂H₁₁NO₂S): C, H, N, S.

(R)-N-Cyclohexyl-2-methyl-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3-carboxamide Hydrochloride (113). Compound 63 (10.5 g, 30 mmol), MeI (1.86 mL, 30 mmol), and NEt₃ (6.7 g, 66 mmol) were dissolved in CHCl₃ (100 mL) and stirred at room temperature for 18 h. The reaction mixture was diluted with CHCl₃ (50 mL) and washed with aqueous NaHCO₃ (30 mL) and with H₂O (30 mL \times 2). The CHCl₃ solution was dried on Na₂SO₄, concentrated, and purified through a silica gel

column (CHCl₃/MeOH, 50:1). The oil product was dissolved in MeOH (50 mL), and a MeOH solution containing 1 N HCl (30 mL) was added to the residue. Precipitated crystals were collected by filtration to provide 113 (7.15 g, 19.6 mmol) in a yield of 65%. The optical purity was 99.9% ee as determined by HPLC (hexane/EtOH, 60:35, Daicel Chemical Industries, Ltd., Chiralpak AS). Mp: 260–261 °C. IR (KBr): 3220, 2940, 2860, 1680, 1545, 760, 730 cm⁻¹. NMR (δ , DMSO-*d*₆): 0.73–2.16 (m, 10 H), 2.56 (m, 3 H), 2.93–3.30 (m, 1 H), 3.40–3.90 (m, 2 H), 3.93–4.50 (m, 1 H), 4.83–4.98 (m, 2 H), 5.67–5.85 (m, 1 H), 7.16–7.90 (m, 4 H). Anal. (C₁₈H₂₄N₂O₃S·HCl): C, H, N, S.

5-HT_{1A} Receptor Binding Assays.¹⁶ Tissue preparation: Male Sprague-Dawley rats (200–250 g, Charles River) were sacrificed by decapitation and their brains removed rapidly and placed in 0.32 M sucrose on ice. The hippocampus was dissected and homogenized in 10 volumes of 50 mM Tris-HCl buffer (pH 7.4). The homogenate was centrifuged at 48000g for 15 min. The resulting pellet was resuspended in Tris buffer and incubated at 30 °C for 20 min followed by centrifugation at 48000g for 15 min. The final pellet was suspended in the binding buffer (50 mM Tris pH 7.7, 0.1% ascorbic acid, 4 mM CaCl₂, and 10 μ M pargyline). [³H]-5-HT binding studies: Tissue preparations (150–200 μ g protein/tube) were incubated in duplicate with 0.5 nM [³H]-8-OH-DPAT (5901.5 GBq/mmol, NEN) in the presence of unlabeled drugs for 30 min at 30 °C. Nonspecific binding was determined with 10 μ M 5-HT. The binding reaction was terminated by filtration under vacuum through GF/C filters. Filters were washed twice with 5 mL of the binding buffer. Radioactivity was determined using an aliquot scintillation counter. The K_i values were calculated from the IC₅₀ by the formula: K_i = IC₅₀/(1 + L*/K*) where K* is the dissociation constant of the labeled ligand and L* is the concentration of labeled ligand.

Water Lick Conflict Test.¹⁷ Male Wistar rats (170–200 g) were used. Rats were deprived of water for 24 h prior to the test. The rats were placed in a test chamber and allowed to locate a drinking spout which gave off mild electric shocks (1.0 mA). Only rats making between 3 and 10 licks during a total of 30 s in this pre-session were used for the animal test. The rats were removed from the chamber, administered compounds and were returned to the home cage for 60 min. The rats were then returned to the test chamber for the 5-min test session. During the 5-min test session, the rats were delivered a shock (2.5 mA) for every drop they drank. The number of shocks received during the 5 min session was recorded automatically.

Passive Avoidance Test.^{18,19} Male ddY mice (20–25 g) were kept in a plastic cage in groups of 10 and allowed free access to dry food pellets and water. The mice were trained in a one-trial step-through passive avoidance task. The apparatus consisted of a small white box (15 cm \times 10 cm \times 9 cm) and a black shock box (15 cm \times 15 cm \times 14 cm) with a hall at the bottom and a grillotined door. During the acquisition test, they were placed in a small lighted compartment. Five seconds later, the door was opened. The mice received a 1 mA foot shock after entering the dark compartment and they were then returned to their home cage. Twenty-four hours later, after the acquisition test, mice were placed in the small lighted box again. Time latency to enter the dark compartment was recorded (maximum = 300 s). Compounds were administered 60 min prior to the acquisition. For evaluation of the effect on scopolamine-induced amnesia, scopolamine 3 mg/kg was administered intraperitoneally 15 min prior to the acquisition test. Compounds were administered 45 min prior to the administration of scopolamine.

Acknowledgment. We thank Mr. I. Fujimastu for helpful discussion and encouragement during the course of the study. We also acknowledge the excellent technical support of members of the synthetic section. We are very grateful to Prof. K. Fujita of Nagasaki University, Faculty of Pharmaceutical Science, for proofreading the manuscript and helpful discussions.

References

- 1) Panicker, K. S.; McNaughton, N. Comparison of the effect of buspirone and chlordiazepoxide on differential reinforcement of low rates of response. *Eur. J. Pharmacol.* 1992, 210, 307–313.

- (2) Murasaki, M. Anxiolytics not related to benzodiazepine receptors. *Neuropsychopharmacology*. 1991, 13, 173-177.
- (3) Garattini, S.; Caccia, C.; Mennini, T. Notes on Buspirone's Mechanism of Action. *J. Clin. Psych.* 1943, 12, 19-24. Hamik, A.; Okseberg, D.; Fischette, D.; Peroutka, S. J. Analysis of Tandoospirone (SM-3977) Interactions with Neurotransmitter Receptor Binding Sites. *Biol. Psych.* 1990, 28, 99-109.
- (4) Kawakubo, H.; Okazaki, K.; Nagatani, T.; Takao, K.; Hasimoto, S.; Sugihara, T. Potent Anticonflict Activity and Lessening of Memory Impairment with a Series of Novel [1]Benzothieno[2,3-c]pyridines and 1,2,3,4-Tetrahydro[1]benzothieno[2,3-c]pyridines. *J. Med. Chem.* 1990, 33, 3110-3116.
- (5) (S)-Form was synthesized by the same synthetic method of Scheme I except for using (S)-thiotryptophan instead of (R)-thiotryptophan.
- (6) Fujihara, H.; Schowen, R. L. Facile, Economical Synthesis of L-[α - ^3H]- α -Amino Acids. *J. Org. Chem.* 1984, 49, 2819-2820.
- (7) Chapman, N. B.; Scrowston, R. M.; Westwood, R. Pharmacologically Active Benzo[b]thiophen Derivatives. Part VIII. Benzo[b]thiophen Analogues of Tryptophan and α -Methyltryptophan, and Some of their 5-Substituted Derivatives. *J. Chem. Soc. C* 1969, 1855-1858.
- (8) Acylase 30000 units was purchased from Amano Pharmaceutical Co., Ltd.
- (9) Weissberger, A.; Kibler, C. J. Methyl Pyruvate (Pyruvic acid, methyl ester). *Organic Syntheses*; Wiley: New York, 1955; Collect. Vol. III, p 610.
- (10) Peterson, M. L.; Way, J. W. Esterification. *Ind. Eng. Chem.* 1958, 50, No. 9, 1335.
- (11) Pictet, A.; Spengler, T. Preparation of Isoquinoline Derivatives by the Reaction of Formaldehyde and Phenylethylamine, Phenylalanine, Tyrosine. *Ber. Dtsch. Chem. Ges.* 1911, 44, 2030.
- (12) Whaley, W. M.; Govindachari, T. R. The Pictet-Spengler Synthesis of Tetrahydroisoquinolines and Related Compounds. *Org. React.* 1951, 6, 151.
- (13) Ong, H. H.; May, E. L. Iminoethanophenanthridines by the Pictet-Spengler Reaction. *J. Heterocycl. Chem.* 1971, 8, 1007.
- (14) Smith, M. A.; Weinstein, B.; Greene, F. D. Cyclic Azo Dioxides. Synthesis and Properties of Bis(o-nitrosobenzyl) Derivatives. *J. Org. Chem.* 1980, 45, 4597-4602.
- (15) Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Paschal, J. W. Syntheses of 6-Oxodecahydroisoquinoline-3-carboxylates. Useful Intermediates for the Preparation of Conformationally Defined Excitatory Amino Acid Antagonists. *J. Org. Chem.* 1991, 56, 4388-4392.
- (16) Yevich, J. P.; New, J. S.; Lobeck, W. G.; Dextraze, P.; Bernstein, E.; Taylor, D. P.; Yocca, F. D.; Eison, M. S.; Temple, D. L., Jr. Synthesis and Biological Characterization of α -(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and Analogues as Potential Atypical Antipsychotic Agents. *J. Med. Chem.* 1992, 35, 4516-4525.
- (17) Vogel, J. R.; Beer, B.; Clody, D. E. A Simple and Reliable Conflict Procedure for Testing Anti-anxiety Agents. *Psychopharmacologia* 1971, 21, 1-7.
- (18) Ghoneim, M. M.; Mewaldt, S. P. Effects of Diazepam and Scopolamine on Storage, Retrieval, and Organizational Processes in Memory. *Psychopharmacologia* 1975, 44, 257-262.
- (19) Komiskey, H. L.; Cook, T. M.; Lin, C. F.; Hayton, W. I. Impairment of Learning or Memory in the Mature and Old Rat by Diazepam. *Psychopharmacology* 1981, 73, 304-305.
- (20) Henry, D.; Block, J. H.; Anderson, J. L.; Carlson, G. R. Use of High-Pressure Liquid Chromatography for Quantitative Structure-Activity Relationship Studies of Sulfonamides and Barbiturates. *J. Med. Chem.* 1976, 19, 619-626.